abstract |
The present invention provides for the treatment of primary headache disorders, particularly migraine, using antagonists of the EP4 receptor for prostaglandin E2. Particular EP4 receptor antagonists include azole compounds of formula (I): wherein R1 is a group such as lower alkyl substituted with carboxy; R2 is hydrogen or lower alkyl, R3 and R4 are aryl optionally substituted with halogen, Q is in which -A1- is a single bond or lower alkylene, is a cyclo group, -A3- is a single bond or lower alkylene, and X is O, NH or S; or a salt or its solvate thereof. |